Source comparison
CJC-1295 Muscle Growth Research: Compound Comparison
CJC-1295 (with DAC) 6–8 days GHRH receptor agonist. Sustained GH secretion from anterior pituitary 12–18% increase in lean tissue vs control when combined with resistance training (12-week rodent model) Once weekly Best choice for long-duration studies requiri
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- 6–8 days
- GHRH receptor agonist. Sustained GH secretion from anterior pituitary
- 12–18% increase in lean tissue vs control when combined with resistance training (12-week rodent model)
- Once weekly
- Best choice for long-duration studies requiring stable GH/IGF-1 elevation without daily injections. Effect dependent on loading stimulus and amino acid availability.
- Modified GRF (1-29)
- 30 minutes
- GHRH receptor agonist. Acute GH pulse generation
- Comparable cumulative effect to CJC-1295 when dosed 2–3×/day, but requires more frequent administration
- 2–3 times daily
- Produces sharper GH peaks but demands multiple daily administrations. Useful for pulsatile secretion research but less practical for sustained anabolic studies.
- MK-677 (Ibutamoren)
- 24 hours
- Ghrelin receptor agonist. Stimulates GH release via hypothalamic pathway
- 2–5% lean mass increase over 8 weeks in clinical trials, with notable increases in appetite and water retention
- Once daily
- Oral bioavailability advantage but mechanism bypasses GHRH pathway entirely. Appetite stimulation complicates controlled feeding protocols.
- Exogenous GH (Somatropin)
- 20–30 minutes
- Direct GH replacement. Bypasses endogenous secretion pathways
- 5–10% lean mass increase in GH-deficient populations; diminishing returns in healthy models due to receptor downregulation
- Multiple daily injections
- Gold standard for GH insufficiency but suppresses endogenous production. Not ideal for research examining natural secretory dynamics.
- GHRP-2
- Ghrelin mimetic. Stimulates GH release via synergistic GHRH pathway activation
- Modest lean mass effects when combined with GHRH analogs; minimal effect as monotherapy
- Synergistic with CJC-1295 but offers limited standalone anabolic value. Primarily used to amplify GH pulse amplitude in combination protocols.